Q/C Technologies, Inc. (QCLS) stock
QCLSNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$0.33+0.01 (+4.05%)
Close on Nov 17, 2026Market cap $2.74MP/E –Yield –
Q/C Technologies r&d expenses
Research and development expenses are spending on new products and technology.
Q/C Technologies's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.80M. For fiscal 2025 it was $3.47M, up 0.9% from the year before. Over ten years it grew 9.5% a year on average. The highest annual figure on record is $9.07M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.47M | +0.9% |
| FY2024 | Dec 31, 2024 | $3.44M | -56.3% |
| FY2023 | Dec 31, 2023 | $7.87M | -13.2% |
| FY2022 | Dec 31, 2022 | $9.07M | +34.4% |
| FY2021 | Dec 31, 2021 | $6.75M | +173.4% |
| FY2020 | Dec 31, 2020 | $2.47M | +791.3% |
| FY2019 | Dec 31, 2019 | $276.79K | -74.0% |
| FY2018 | Dec 31, 2018 | $1.06M | -15.6% |
| FY2017 | Dec 31, 2017 | $1.26M | +6.0% |
| FY2016 | Dec 31, 2016 | $1.19M | -15.5% |
| FY2015 | Dec 31, 2015 | $1.41M | +53.5% |
| FY2014 | Dec 31, 2014 | $916.31K | -9.0% |
| FY2013 | Dec 31, 2013 | $1.01M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $236.13K | -73.0% |
| Q1 FY2026 | Mar 31, 2026 | $510.53K | -67.0% |
| Q4 FY2025 | Dec 31, 2025 | $696.50K | -38.5% |
| Q3 FY2025 | Sep 30, 2025 | $356.35K | -70.3% |
| Q2 FY2025 | Jun 30, 2025 | $873.47K | -70.5% |
| Q1 FY2025 | Mar 31, 2025 | $1.55M | -19.2% |
| Q4 FY2024 | Dec 31, 2024 | $1.13M | -49.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.20M | +55.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.96M | +19.8% |
| Q3 FY2023 | Sep 30, 2023 | $1.91M | +6.0% |
| Q2 FY2023 | Jun 30, 2023 | $2.22M | +2.8% |
| Q1 FY2023 | Mar 31, 2023 | $770.43K | -70.7% |
| Q4 FY2022 | Dec 31, 2022 | $2.47M | +240.0% |
| Q3 FY2022 | Sep 30, 2022 | $1.80M | -39.5% |
| Q2 FY2022 | Jun 30, 2022 | $2.16M | +30.3% |
| Q1 FY2022 | Mar 31, 2022 | $2.63M | +94.7% |
| Q4 FY2021 | Dec 31, 2021 | $726.54K | -60.2% |
| Q3 FY2021 | Sep 30, 2021 | $2.98M | +71.1% |
| Q2 FY2021 | Jun 30, 2021 | $1.66M | -13.3% |
| Q1 FY2021 | Mar 31, 2021 | $1.35M | -45.6% |
| Q4 FY2020 | Dec 31, 2020 | $1.82M | +2505.1% |
| Q3 FY2020 | Sep 30, 2020 | $1.74M | +2928.2% |
| Q2 FY2020 | Jun 30, 2020 | $1.92M | +3045.9% |
| Q1 FY2020 | Mar 31, 2020 | $2.48M | +2709.2% |
| Q4 FY2019 | Dec 31, 2019 | $69.99K | -65.6% |
| Q3 FY2019 | Sep 30, 2019 | $57.50K | -64.3% |
| Q2 FY2019 | Jun 30, 2019 | $60.91K | -76.5% |
| Q1 FY2019 | Mar 31, 2019 | $88.39K | -79.9% |
| Q4 FY2018 | Dec 31, 2018 | $203.29K | -30.1% |
| Q3 FY2018 | Sep 30, 2018 | $160.87K | -53.8% |
| Q2 FY2018 | Jun 30, 2018 | $259.12K | +1.2% |
| Q1 FY2018 | Mar 31, 2018 | $439.97K | +77.7% |
| Q2 FY2017 | Jun 30, 2017 | $290.84K | -9.7% |
| Q1 FY2017 | Mar 31, 2017 | $348.44K | -4.1% |
| Q4 FY2016 | Dec 31, 2016 | $256.01K | – |
| Q3 FY2016 | Sep 30, 2016 | $247.58K | – |
| Q2 FY2016 | Jun 30, 2016 | $321.99K | – |
| Q1 FY2016 | Mar 31, 2016 | $363.29K | – |
See a number that looks wrong?